Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a clinical-stage biotechnology company advancing targeted therapies for cancer treatment, with a focus on immuno-oncology and precision medicine. This page provides investors and industry stakeholders with timely updates on the company’s clinical trials, strategic collaborations, and regulatory milestones.
Access curated press releases and news articles covering Curis’s pipeline developments, including its lead candidate emavusertib, partnership updates with Aurigene and Genentech, and financial performance. The resource is designed to help users track progress across hematologic and solid tumor indications while staying informed about licensing agreements and scientific advancements.
Content spans clinical trial results, FDA designations, earnings reports, and research publications. Bookmark this page for direct access to verified updates on Curis’s innovative approaches to modulating cancer pathways and expanding treatment options.
Curis, Inc. (NASDAQ: CRIS) provided a business update and financial results for Q1 2024. The company will present clinical data on emavusertib for leukemia patients, updated data for R/R AML, and upcoming milestones for ongoing studies. Financially, Curis reported a net loss of $11.9 million, a decrease in revenue, and increased R&D and G&A expenses. Cash, cash equivalents, and investments totaled $40.7 million as of March 31, 2024.
Curis, Inc. (NASDAQ: CRIS) will release its first quarter 2024 financial results on May 7, 2024, followed by a conference call. The company is focused on developing emavusertib (CA-4948), an IRAK4 inhibitor. Investors can access the call via phone or the company's website.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
